Russian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
antiandrogens/диарея
Ссылка сохраняется в буфер обмена
Страница 1 от 39 полученные результаты
Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
This article provides a summary of the pharmacodynamic properties of major antiandrogens as well as an extensive review of their tolerability. Presently there are two classes of androgen receptor antagonists: the so-called pure, non-steroidal antiandrogens which include flutamide, nilutamide and the
Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Maximum androgen blockade, a relatively recent development in the treatment of prostate cancer, combines medical or surgical castration with antiandrogen therapy. A large randomized study comparing the non-steroidal antiandrogen, bicalutamide, with flutamide, each in combination with luteinizing
Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
This review compares the tolerability profiles of the three currently available nonsteroidal antiandrogens, flutamide, bicalutamide and nilutamide. Pharmacological effects associated with blockade of the androgen receptor are frequent with all three drugs. Gynecomastia and breast pain are seen more
What implications do the tolerability profiles of antiandrogens and other commonly used prostate cancer treatments have on patient care?
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
OBJECTIVE
Increased awareness of prostate cancer has led to earlier initiation of therapy, and the potential for a longer duration of treatment has led to a stronger emphasis on tolerability. Historically, the mainstay of treatment of hormone-sensitive prostate cancer has been castration-based
[Clinical evaluation of flutamide, a pure antiandrogen, in prostatic cancer phase II dose-finding study].
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
The phase II study of flutamide, a pure anti-androgen, was performed to estimate the clinical doses on 165 hormone untreated or treated patients with prostatic cancer. The hormone-untreated patients were given orally flutamide of 90, 375, 750 or 1,125 mg/day in three divided doses daily for 12
Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first- to second-generation antiandrogen.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Many physicians use combined androgen blockade in the form of a luteinizing hormone-releasing hormone analog or bilateral orchiectomy in combination with a non-steroidal antiandrogen to offer patients a potentially more effective treatment than castration alone. Three non-steroidal anti-androgens
Flutamide: an antiandrogen for advanced prostate cancer.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Flutamide is a nonsteroidal pure antiandrogen that acts by inhibiting the uptake and/or binding of dihydrotestosterone to the target cell receptor, thus interfering with androgen action. Flutamide is well absorbed orally and extensively metabolized; its active metabolite, 2-hydroxyflutamide, is
Efficacy and safety of combined androgen blockade with antiandrogen for advanced prostate cancer.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Steroid hormones and Tourette's syndrome: early experience with antiandrogen therapy.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
We report here the first use in Tourette's syndrome of the nonsteroidal androgen receptor blocking agent flutamide. One man and one woman underwent open trials of the medication, and a second man participated in a placebo-controlled, double-blind crossover trial. Improvement in tic symptoms ranged
Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Enzalutamide (MDV3100, Xtandi, Medivation\Astellas) is an oral inhibitor of androgen receptor signaling that blocks androgen receptor interaction, inhibits translocation of the androgen receptor to the nucleus, impairs androgen receptor binding to DNA, and inhibits coactivator recruitment and
Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
BACKGROUND
The treatment for prostate cancer patients with biochemical failure after local therapy remains controversial. Peripheral androgen blockade using a combination of a 5-alpha reductase inhibitor and an antiandrogen may allow control of the prostate-specific antigen (PSA). Because
Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
OBJECTIVE
To compare in a randomized clinical trial the therapeutic efficacy of the nonsteroidal antiandrogen flutamide 250 mg tid to testicular androgen suppression by orchidectomy in patients with metastatic prostate cancer.
METHODS
Between 1989 and 1991, 104 patients aged 74 +/- 8 years with
Complete androgen blockade as treatment for advanced prostate cancer: clinical response and side-effects.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Treatment of advanced prostatic cancer is currently based on hormonal manipulation. In 1982 Labrié supported a new concept of hormonal treatment based on complete androgen blockade. The objective of this study was to evaluate the effects of total androgen suppression, achieved by the combination of
Flutamide in treatment of benign prostatic hypertrophy.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
A multicenter, randomized, double-blind study was undertaken to evaluate the efficacy of the antiandrogen flutamide in treating patients with urinary obstruction caused by benign prostatic hypertrophy (BPH). Patients were randomized to either flutamide (750 mg/d) or a placebo. Prostate size
[The role of bicalutamide in the treatment of prostate cancer].
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Bicalutamide is an effective, non-steroidal antiandrogen, suitable for oral, once daily administration. Bicalutamide 50 mg plus LHRHa is at least as effective as flutamide plus LHRHa in terms of survival and time to progression. Monotherapy with bicalutamide 150 mg once daily has similar survival
Самая полная база данных о лекарственных травах, подтвержденная наукой
- Работает на 55 языках
- Травяные лекарства, подтвержденные наукой
- Распознавание трав по изображению
- Интерактивная карта GPS - отметьте травы на месте (скоро)
- Прочтите научные публикации, связанные с вашим поиском
- Ищите лекарственные травы по их действию
- Организуйте свои интересы и будьте в курсе новостей исследований, клинических испытаний и патентов
Введите симптом или заболевание и прочтите о травах, которые могут помочь, введите лекарство и узнайте о болезнях и симптомах, против которых оно применяется.
* Вся информация основана на опубликованных научных исследованиях.
